Full Name
Christopher Bravery
Hospital/Organisation/Company
IABS / AdvBiols
Speaker Bio
Christopher Bravery is an experienced Regulatory Scientist with more than 15 years of expertise in advanced therapies, including ATMPs, cell, gene and tissue products, as well as other regenerative medicine products and protein therapeutics. He is the founder of Consulting on Advanced Biologicals Ltd, established at the end of 2009 to focus specifically on the regenerative medicine sector. Through Advbiols Ltd, he provides EU regulatory services to the regenerative medicine industry, as well as business and regulatory research and analysis aimed at identifying and addressing the key barriers to the successful commercialisation of regenerative medicine products.
Christopher brings a rare combination of scientific depth, regulatory expertise, and industry insight, built through senior roles in both biotechnology companies and regulatory authorities. He spent eight years in biotech, notably with Imutran Ltd, a Novartis Pharma AG company, and Intercytex, before joining the MHRA as a Quality (CMC) Assessor in the Biologicals and Biotechnology Unit. During his time at the MHRA, he contributed to the national implementation of the new Advanced Therapies Regulation and was also involved at European level through his participation in the CHMP Cell Products Working Party (CPWP), including work on implementation at EMA level and the drafting of guidelines.
He provides high-level regulatory science support in quality/CMC and preclinical development at ICH standards, together with expert guidance on EU regulatory procedures and legislation. His deep knowledge of the European regulatory framework includes extensive experience with EU clinical trial applications (IMPDs), EMA marketing authorisation applications (MAAs), and post-authorisation procedures such as variations. This expertise has been further strengthened through many years of advising a wide variety of clients across the life sciences and regenerative medicine sectors.
Christopher holds a PhD in xenotransplantation immunology, which forms the foundation of his scientific expertise. His broader background also includes target validation, protein chemistry, metrology, tissue engineering, renal medicine, molecular biology, and stem cell research. He is recognised for consistently delivering high-quality results on time and within budget, while maintaining a proactive and client-focused approach that has resulted in strong customer satisfaction and a high level of repeat business.
An enthusiastic and self-motivated professional, Christopher thrives on scientific and regulatory challenges. He is also an accomplished communicator, with extensive experience in delivering presentations, workshops, and training courses in biotechnology and advanced therapies at both national and international level. His expertise is further reflected in numerous peer-reviewed publications.
Christopher brings a rare combination of scientific depth, regulatory expertise, and industry insight, built through senior roles in both biotechnology companies and regulatory authorities. He spent eight years in biotech, notably with Imutran Ltd, a Novartis Pharma AG company, and Intercytex, before joining the MHRA as a Quality (CMC) Assessor in the Biologicals and Biotechnology Unit. During his time at the MHRA, he contributed to the national implementation of the new Advanced Therapies Regulation and was also involved at European level through his participation in the CHMP Cell Products Working Party (CPWP), including work on implementation at EMA level and the drafting of guidelines.
He provides high-level regulatory science support in quality/CMC and preclinical development at ICH standards, together with expert guidance on EU regulatory procedures and legislation. His deep knowledge of the European regulatory framework includes extensive experience with EU clinical trial applications (IMPDs), EMA marketing authorisation applications (MAAs), and post-authorisation procedures such as variations. This expertise has been further strengthened through many years of advising a wide variety of clients across the life sciences and regenerative medicine sectors.
Christopher holds a PhD in xenotransplantation immunology, which forms the foundation of his scientific expertise. His broader background also includes target validation, protein chemistry, metrology, tissue engineering, renal medicine, molecular biology, and stem cell research. He is recognised for consistently delivering high-quality results on time and within budget, while maintaining a proactive and client-focused approach that has resulted in strong customer satisfaction and a high level of repeat business.
An enthusiastic and self-motivated professional, Christopher thrives on scientific and regulatory challenges. He is also an accomplished communicator, with extensive experience in delivering presentations, workshops, and training courses in biotechnology and advanced therapies at both national and international level. His expertise is further reflected in numerous peer-reviewed publications.